125 related articles for article (PubMed ID: 37899201)
1. [Management of adverse effects in CAR T-cell therapy].
Goto H
Rinsho Ketsueki; 2023; 64(9):1203-1212. PubMed ID: 37899201
[TBL] [Abstract][Full Text] [Related]
2. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Perez A; Al Sagheer T; Nahas GR; Linhares YPL
Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
[TBL] [Abstract][Full Text] [Related]
3. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.
Hoyt R; Ye Z; Dasgupta A
Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457
[TBL] [Abstract][Full Text] [Related]
4. How I treat refractory CRS and ICANS after CAR T-cell therapy.
Jain MD; Smith M; Shah NN
Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
[TBL] [Abstract][Full Text] [Related]
5. Cytokines in CAR T Cell-Associated Neurotoxicity.
Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
Front Immunol; 2020; 11():577027. PubMed ID: 33391257
[TBL] [Abstract][Full Text] [Related]
6. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.
Chen LY; Kothari J
Curr Opin Support Palliat Care; 2024 Jun; 18(2):92-99. PubMed ID: 38652455
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
8. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy.
Gutierrez C; Neilan TG; Grover NS
Blood; 2023 May; 141(20):2452-2459. PubMed ID: 36827628
[TBL] [Abstract][Full Text] [Related]
9. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
[TBL] [Abstract][Full Text] [Related]
10. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
Song KW; Scott BJ; Lee EQ
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):827-839. PubMed ID: 37938472
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
13. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A; Hueso T; Laparra A; Bige N; Ouali K; Cauquil C; Stoclin A; Danlos FX; Hollebecque A; Ribrag V; Gazzah A; Goldschmidt V; Baldini C; Suzzoni S; Bahleda R; Besse B; Barlesi F; Olivier L; Massard C; Marabelle A; Castilla-Llorente C; Champiat S; Michot JM
Eur J Cancer; 2024 May; 205():114075. PubMed ID: 38733717
[TBL] [Abstract][Full Text] [Related]
14. Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review.
Frey C; Cherniawsky H; Etminan M
Eur J Haematol; 2024 Jul; 113(1):66-71. PubMed ID: 38549191
[TBL] [Abstract][Full Text] [Related]
15. Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation.
Penack O; Peczynski C; Boreland W; Wolff D; Moiseev I; Schoemans H; Koenecke C; Graham C; Peric Z
Haematologica; 2024 May; ():. PubMed ID: 38813730
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?
Parol W; Anderson GSF; Chapman MA
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):241-244. PubMed ID: 35686653
[No Abstract] [Full Text] [Related]
17. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Apr; ():. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
18. CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.
Elmarasi M; Elkonaissi I; Elsabagh AA; Elsayed E; Elsayed A; Elsayed B; Elmakaty I; Yassin M
Int Immunopharmacol; 2024 May; 135():112312. PubMed ID: 38788449
[TBL] [Abstract][Full Text] [Related]
19. Rapidly progressing vulvar soft tissue infection as a result of severe hypogammaglobulinemia following CAR T-cell therapy.
Cotangco K; Manrriquez EN; Salani R
Gynecol Oncol Rep; 2022 Aug; 42():101016. PubMed ID: 35711731
[TBL] [Abstract][Full Text] [Related]
20. Hematology: the specialty with a record number of new approvals.
Gavriilaki E
Front Med (Lausanne); 2024; 11():1385052. PubMed ID: 38487026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
